Dr. Basem William, MD
Hematology & Oncology (Hematology & Oncology Physician)
1050 Delaware Ave
Marion, OH 43302
Who else practices at this address →
Marion County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 76
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
OH license 35-099331 -
Hospitalist Physician
ME license 016881
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Riverside Methodist Hospital Columbus, OH
- Grant Medical Center Columbus, OH
Medical groups
- Ohiohealth Corporation (2,314 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 76
- Services billed
- 345
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 270 | 23 |
| Established patient office or other outpatient visit, 30-39 minutes | 79 | 29 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 25 | 16 |
| New patient office or other outpatient visit, 60-74 minutes | 25 | 25 |
| Hospital discharge day management, more than 30 minutes | 22 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Marion, OH | 42 |
| Brukinsa (zanubrutinib) | 30 |
| Levothyroxine Sodium Other prescribers in Marion, OH | 27 |
| Prednisone Other prescribers in Marion, OH | 20 |
| Entecavir | 17 |
| Prochlorperazine Maleate Other prescribers in Marion, OH | 15 |
| Bexarotene | 15 |
| Ojjaara (momelotinib dihydrochloride) | 14 |
| Vitamin D2 (ergocalciferol (vitamin d2)) Other prescribers in Marion, OH | 14 |
| Imbruvica (ibrutinib) | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 32 payments worth $10,014 in total to this clinician.
| Kyowa Kirin, Inc. | $4,437 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $2,913 |
| Adaptive Biotechnologies Corporation | $1,757 |
| Karyopharm Therapeutics Inc. | $252 |
| Incyte Corporation | $180 |
| Syndax Pharmaceuticals, Inc. | $148 |
| Sanofi-aventis U.S. LLC | $120 |
| National Marrow Donor Program | $103 |
| Compensation for services other than consulting (speaking, faculty) | $4,388 |
|---|---|
| Consulting Fee | $2,870 |
| Food and Beverage | $1,408 |
| Travel and Lodging | $1,260 |
| Education | $88.10 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Nov 19, 2025 | Consulting Fee | $2,870 |
| Kyowa Kirin, Inc. Jul 7, 2025 | Compensation for services other than consulting (speaking, faculty) POTELIGEO · MONOCLONAL ANTIBODY | $2,438 |
| Kyowa Kirin, Inc. Sep 29, 2025 | Compensation for services other than consulting (speaking, faculty) POTELIGEO · MONOCLONAL ANTIBODY | $1,950 |
| Adaptive Biotechnologies Corporation Feb 13, 2025 | Travel and Lodging clonoSEQ · Devices · travel to Houston, TX | $630 |
| Adaptive Biotechnologies Corporation Feb 13, 2025 | Travel and Lodging clonoSEQ · Devices · travel to Houston, TX | $483 |
| Incyte Corporation May 22, 2025 | Education | $65.00 |
| Adaptive Biotechnologies Corporation Feb 13, 2025 | Travel and Lodging clonoSEQ · Devices · travel to Houston, TX | $57.60 |
| Adaptive Biotechnologies Corporation Feb 13, 2025 | Travel and Lodging clonoSEQ · Devices · travel to Houston, TX | $48.12 |
| Adaptive Biotechnologies Corporation Feb 13, 2025 | Travel and Lodging clonoSEQ · Devices · travel to Houston, TX | $40.98 |
| AstraZeneca Pharmaceuticals LP Apr 16, 2025 | Education in-kind Company’s descriptionJournal Article | $23.10 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $133,961 in research payments for these studies, mostly to the institutions running them.
- A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis
Karyopharm Therapeutics Inc. - A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Beone Medicines Ltd. · Recruiting · NCT06742996 - M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma
AbbVie Inc. - A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
AbbVie Inc. · Active, not recruiting · NCT05578976 - RealMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (realMIND)
Incyte Corporation - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
AbbVie Inc. · Active, not recruiting · NCT05451810 - M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
AbbVie Inc. - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.